论文部分内容阅读
目的:评估海狗油ω-3多不饱和脂肪酸胶丸治疗非酒精性脂肪肝(NAFLD)的临床效果。方法:将2007年1月至2013年1月广州医科大学附属市第八人民医院收治的43例NAFLD患者随机分为试验组(26例)和对照组(17例),试验组服用海狗油ω-3多不饱和脂肪酸胶丸,对照组服用安慰剂,共24周。对比治疗前后病理分级、B超评分及丙氨酸基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、体质量指数(BMI)、甘油三酯(TG)、总胆固醇(TC)、胰岛素抵抗指数(HOMA-IR)等指标差异。结果:经24周治疗后,试验组B超评分、TG、BMI、HOMA-IR较治疗前明显降低(P<0.05),与对照组比较也明显较低(P<0.05)。两组肝脂肪变程度、炎症、纤维化、ALT、AST、TC比较,差异无统计学意义(P>0.05)。结论:海狗油ω-3多不饱和脂肪酸胶丸能降低NAFLD患者TG、BMI、HOMA-IR水平,改善脂肪肝B超分级,但与病理组织学改变的关系不明显。
Objective: To evaluate the clinical effect of seal oil ω-3 polyunsaturated fatty acid capsule in the treatment of non-alcoholic fatty liver disease (NAFLD). Methods: Forty-three patients with NAFLD admitted to the Eighth People’s Hospital of Guangzhou Medical University from January 2007 to January 2013 were randomly divided into test group (26 cases) and control group (17 cases) -3 polyunsaturated fatty acid capsules, the control group taking placebo for a total of 24 weeks. The pathological grade, B-ultrasound, ALT, AST, TC, TG and TC were compared before and after treatment. , Insulin resistance index (HOMA-IR) and other indicators of differences. Results: After 24 weeks of treatment, the scores of B-ultrasound, TG, BMI and HOMA-IR of the experimental group were significantly lower than those before treatment (P <0.05), but also significantly lower than those of the control group (P <0.05). There was no significant difference in hepatic steatosis, inflammation, fibrosis, ALT, AST and TC between the two groups (P> 0.05). Conclusion: Seawater oil ω-3 polyunsaturated fatty acid capsules can reduce the levels of TG, BMI and HOMA-IR in NAFLD patients and improve the grade of B-ultrasound of fatty liver, but the relationship between them is not obvious with the histopathological changes.